Contrast-induced nephropathy (CIN) and post-procedural acute kidney injury (AKI) are among the iatrogenic complications with the greatest economic impact in vascular care. An episode of AKI associated with imaging procedures increases the average hospital length of stay by approximately 3–5 days. In the most severe cases, additional costs arise from acute dialysis sessions and intermediate or intensive care management, with total costs that may exceed €5,000 per event.
The proportion of patients with chronic kidney disease (CKD), diabetes, or multiple comorbidities undergoing peripheral vascular interventions or EVAR continues to increase across Europe. Systematically reducing exposure to iodinated contrast media is therefore more than a clinical decision—it is a healthcare management strategy with direct, measurable effects on departmental costs and resource utilization.
The most immediate economic benefit is the reduction in post-procedural hospital stay. Patients who develop AKI following angiography with iodinated contrast typically remain hospitalized for an additional 3–5 days compared with patients who experience no renal complications. In vascular surgery departments, the average daily cost of hospitalization in Italy is estimated to range from €600 to €900, depending on the institution and the required level of care.
In a center performing approximately 300 peripheral vascular procedures each year, where 40% of patients are at increased renal risk (CKD stage 3–5 or eGFR below 60 mL/min/1.73 m²), a 30% reduction in AKI incidence corresponds to approximately 12–15 prevented AKI events annually. The savings associated with avoided additional hospitalization alone are therefore estimated to range between €21,600 and €67,500 per year, depending on patient risk profile and institutional practice.
Every prevented episode of AKI also avoids the costs of related treatments. A single session of acute inpatient dialysis typically costs between €500 and €1,200. Patients who develop severe contrast-associated nephropathy requiring three to five dialysis sessions generate additional costs ranging from approximately €1,500 to €6,000 per episode, excluding intensive monitoring, nephrology consultations, and supportive pharmacological therapy.
Thirty-day readmissions resulting from renal complications represent an additional cost that can be quantified using the Diagnosis-Related Group (DRG) reimbursement associated with the readmission. In DRG-based reimbursement systems, unplanned readmissions within 30 days are frequently associated with financial penalties or reduced reimbursement, making systematic prevention of renal complications economically advantageous in addition to its clinical benefits.
One frequently underestimated economic benefit is the reduction in pharmaceutical expenditure for iodinated contrast media. Centers that adopt CO₂-first or Zero Contrast protocols typically reduce iodinated contrast consumption by between 40% and 80% compared with baseline practice, depending on the proportion of eligible procedures and the renal risk profile of their patient population.
In a high-volume vascular center with an annual iodinated contrast media budget of approximately €30,000–50,000, direct savings may range from €12,000 to €40,000 per year. These savings are additive to the costs avoided through the prevention of renal complications, strengthening the overall business case for implementing a structured CO₂ angiography program, even under conservative assumptions.
Diagnosis-Related Group (DRG) reimbursement systems reward efficient procedural management with fewer complications. A patient undergoing peripheral angiography without developing AKI generally generates lower resource utilization than a patient who requires prolonged hospitalization, dialysis, or treatment for renal complications. Consequently, systematic reduction of renal complications improves the department's DRG case mix while increasing average reimbursement per treated patient.
A structured CO₂ program incorporating digital traceability of injection parameters also enables objective comparison of clinical outcomes before and after implementation. This supports internal quality audits, hospital accreditation processes, and reporting to hospital management, regional vascular networks, and Health Technology Assessment (HTA) committees. The Angiodroid system provides this level of procedural traceability as an integral component of the angiography workflow.
The ROI of a CO₂ angiography program is based on the concept of avoided costs. The first step is to estimate how many episodes of AKI can be prevented over a 12-month period by applying the reductions in AKI incidence reported in the scientific literature—including data from the KID Trial and multicenter real-world European studies—to the institution's own patient population and procedural volume.
Each prevented episode of AKI represents savings associated with avoided additional hospitalization, acute dialysis, and potential hospital readmissions. These cumulative economic benefits should then be compared with the investment required to implement the CO₂ program, including the automated CO₂ injector, annual consumables, maintenance, and staff training. In high-volume centers treating a substantial proportion of patients at increased renal risk, the investment typically reaches its payback period within 12 to 24 months.
For each episode of AKI avoided, estimated savings include approximately €1,800–4,500 from reduced hospital length of stay (3–5 days at €600–900 per day), €1,500–6,000 from avoided acute dialysis (3–5 sessions at €500–1,200 each), as well as the costs associated with preventing 30-day readmissions. Overall, the estimated savings per prevented AKI episode range from approximately €3,000 to more than €10,000, depending on the severity of the complication and the patient's clinical profile.
The payback period for a CO₂ angiography program is generally between 12 and 24 months in centers treating a substantial number of patients at increased renal risk. The speed of return on investment depends on the annual procedural volume, the proportion of patients with CKD or diabetes, and the institution's baseline incidence of AKI. A center performing approximately 300 vascular procedures per year, with around 40% of patients at increased renal risk, may often achieve break-even within the first year.
Centers implementing CO₂-first or Zero Contrast protocols for peripheral vascular procedures typically reduce iodinated contrast consumption by approximately 40% to 80% compared with baseline practice. From an economic perspective, this may translate into direct annual savings of approximately €12,000–40,000 on the contrast media budget in high-volume centers, depending on the proportion of eligible procedures and the unit cost of the contrast agent used.
By reducing renal complications, CO₂ angiography can improve the department's Diagnosis-Related Group (DRG) case mix. Patients who do not develop AKI generally require fewer healthcare resources than those experiencing renal complications, dialysis, or prolonged hospitalization. In addition, preventing unplanned 30-day readmissions may reduce reimbursement penalties in DRG-based healthcare systems, improving both average reimbursement per case and the overall financial sustainability of the department.